Listed biotech firm set to raise £6.5m

MANCHESTER biotech company Epistem Holdings is to push ahead with its bid to secure equity funding of £6.5m to broaden the portfolio of its Genedrive tests, developed to fight infectious diseases such as TB across the globe.

The listed company, as a result, has agreed to a request from selected shareholders and potential investors to extend the maturity date of an $8m bond.

The company has announced that it has recently received a non-binding investment committee approved commitment from Calculus Capital, a U... You can carry on reading for free, but you have reached the maximum number of pages an unregistered user can view. To register for an account, click here or login below...